What do systematic reviews say?

PCC vs FVIIa

• Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 256 participants
  Moderate

Exercise vs no exercise

It is very uncertain whether exercise changes all‐cause mortality compared with no exercise (very low certainty).

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.26, 2.68]
  2 studies · 131 participants
  Very low

Exercise vs no exercise

The review found no eligible studies for this question.

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs no exercise

It is very uncertain whether exercise changes all‐cause hospitalisation compared with no exercise (very low certainty).

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  RR 2.72 [0.11, 65.56]
  1 study · 122 participants
  Very low

Exercise vs no exercise

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 150 participants
  Very low

Exercise vs no exercise

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 150 participants
  Very low

Exercise vs no exercise

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 139 participants
  Very low

Exercise vs no exercise

• Exercise‐based cardiac rehabilitation for adults after heart valve surgery 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 139 participants
  Very low

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in in‐hospital postoperative mortality compared with placebo (moderate certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.83 [0.33, 2.07]
  5 studies · 313 participants
  Moderate

Any glucocorticoid vs placebo

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 421 participants
  High

Any glucocorticoid vs placebo

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 421 participants
  High

Any glucocorticoid vs placebo

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 176 participants
  Moderate

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.83 [0.33, 2.07]
  5 studies · 313 participants
  Moderate

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.4 [0.07, 2.46]
  3 studies · 109 participants
  Moderate

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in failure to separate from CPB compared with placebo (low certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 3.92]
  1 study · 40 participants
  Low

Prophylactic levosimendan vs usual care

Prophylactic levosimendan showed no clear difference in mortality compared with standard treatment (low certainty).

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  RR 0.47 [0.12, 1.82]
  3 studies · 123 participants
  Low

Prophylactic levosimendan vs usual care

Prophylactic levosimendan showed no clear difference in low cardiac output syndrome (LCOS) compared with standard treatment (low certainty).

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  RR 0.64 [0.39, 1.04]
  2 studies · 83 participants
  Low

Prophylactic levosimendan vs usual care

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 188 participants
  Low

Prophylactic levosimendan vs usual care

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 75 participants
  Low

Prophylactic levosimendan vs usual care

• Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 208 participants
  Low